Geo Capital Gestora de Recursos Ltd Has $2.15 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Geo Capital Gestora de Recursos Ltd lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6,455.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,130 shares of the medical research company's stock after purchasing an additional 4,067 shares during the period. Thermo Fisher Scientific accounts for 2.8% of Geo Capital Gestora de Recursos Ltd's portfolio, making the stock its 18th largest holding. Geo Capital Gestora de Recursos Ltd's holdings in Thermo Fisher Scientific were worth $2,149,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of TMO. Geode Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 1.7% in the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after purchasing an additional 127,564 shares during the period. Coldstream Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 11.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock valued at $5,972,000 after acquiring an additional 995 shares during the period. Greenwood Gearhart Inc. boosted its holdings in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after acquiring an additional 1,837 shares during the period. Nordea Investment Management AB grew its position in shares of Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after purchasing an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC lifted its holdings in Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after purchasing an additional 618 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TMO shares. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 31st. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Raymond James reiterated an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, Wells Fargo & Company raised their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $653.23.

Thermo Fisher Scientific Price Performance

TMO traded down $0.94 on Wednesday, reaching $513.40. The stock had a trading volume of 1,216,076 shares, compared to its average volume of 1,535,513. The firm has a 50-day moving average of $544.56 and a 200-day moving average of $554.22. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a market capitalization of $193.68 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.